Agarwal told CNBC-TV18, "Nectar Lifesciences is into semi synthetic penicillin and cephalosporins with good number of clients, more than 300 clients they have and with good names like Ranbaxy, Cipla and Alembic in their portfolio. The company has entered into EU and US markets and into CRAMS business. This year's EPS was around Rs 35 and going forward, I think 40%-50% jump in its earning is very much possible. I would suggest a hold and a buy on dips."
